

Giuseppe Losurdo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/975446/publications.pdf>

Version: 2024-02-01

93
papers

1,809
citations

257357

24
h-index

330025

37
g-index

93
all docs

93
docs citations

93
times ranked

2575
citing authors

#	ARTICLE	IF	CITATIONS
1	Curcumin and Colorectal Cancer: From Basic to Clinical Evidences. International Journal of Molecular Sciences, 2020, 21, 2364.	1.8	133
2	How antibiotic resistances could change <i>Helicobacter pylori</i> treatment: A matter of geography?. World Journal of Gastroenterology, 2013, 19, 8168.	1.4	94
3	Probiotic monotherapy and <i>Helicobacter pylori</i> eradication: A systematic review with pooled-data analysis. World Journal of Gastroenterology, 2018, 24, 139-149.	1.4	78
4	Escherichia coli Nissle 1917 in Ulcerative Colitis Treatment: Systematic Review and Meta-analysis. Journal of Gastrointestinal and Liver Diseases, 2020, 24, 499-505.	0.5	77
5	Extra-intestinal manifestations of non-celiac gluten sensitivity: An expanding paradigm. World Journal of Gastroenterology, 2018, 24, 1521-1530.	1.4	59
6	Nonalcoholic Fatty Liver Disease in Inflammatory Bowel Disease: Prevalence and Risk Factors. Inflammatory Bowel Diseases, 2018, 24, 1589-1596.	0.9	58
7	Intestinal microbiota: The explosive mixture at the origin of inflammatory bowel disease?. World Journal of Gastrointestinal Pathophysiology, 2014, 5, 550.	0.5	54
8	Hydradenitis suppurativa and inflammatory bowel disease: An unusual, but existing association. World Journal of Gastroenterology, 2016, 22, 4802.	1.4	49
9	Systematic review with meta-analysis: de novo non-alcoholic fatty liver disease in liver-transplanted patients. Alimentary Pharmacology and Therapeutics, 2018, 47, 704-714.	1.9	46
10	Quadruple Rescue erapy aer First and Second Line Failure for Helicobacter pylori Treatment: Comparison between Two Tetracycline-Based Regimens. Journal of Gastrointestinal and Liver Diseases, 2020, 23, 367-370.	0.5	45
11	Optimizing proton pump inhibitors in <i>Helicobacter pylori</i> treatment: Old and new tricks to improve effectiveness. World Journal of Gastroenterology, 2019, 25, 5097-5104.	1.4	45
12	Systematic review with meta-analysis: post-operative complications and mortality risk in liver transplant candidates with obesity. Alimentary Pharmacology and Therapeutics, 2017, 46, 236-245.	1.9	43
13	Breath Tests for the Non-invasive Diagnosis of Small Intestinal Bacterial Overgrowth: A Systematic Review With Meta-analysis. Journal of Neurogastroenterology and Motility, 2020, 26, 16-28.	0.8	38
14	Noninvasive molecular analysis of <i>Helicobacter pylori</i> : Is it time for tailored first-line therapy?. World Journal of Gastroenterology, 2017, 23, 2453.	1.4	37
15	The Influence of Small Intestinal Bacterial Overgrowth in Digestive and Extra-Intestinal Disorders. International Journal of Molecular Sciences, 2020, 21, 3531.	1.8	37
16	Small intestinal bacterial overgrowth and celiac disease: A systematic review with pooled data analysis. Neurogastroenterology and Motility, 2017, 29, e13028.	1.6	35
17	Primary clarithromycin resistance to <i>Helicobacter pylori</i> : Is this the main reason for triple therapy failure?. World Journal of Gastrointestinal Pathophysiology, 2013, 4, 43.	0.5	34
18	Seronegative celiac disease: where is the specific setting?. Gastroenterology and Hepatology From Bed To Bench, 2015, 8, 110-6.	0.6	32

#	ARTICLE	IF	CITATIONS
19	Ulcerative colitis: From inflammation to cancer. Do estrogen receptors have a role?. World Journal of Gastroenterology, 2014, 20, 11496.	1.4	31
20	Seronegative Celiac Disease and Immunoglobulin Deficiency: Where to Look in the Submerged Iceberg?. Nutrients, 2015, 7, 7486-7504.	1.7	31
21	Macronutrient intakes in obese subjects with or without small intestinal bacterial overgrowth: an alimentary survey. Scandinavian Journal of Gastroenterology, 2016, 51, 277-280.	0.6	30
22	The Puzzle of Coccoid Forms of <i>Helicobacter pylori</i> : Beyond Basic Science. Antibiotics, 2020, 9, 293.	1.5	30
23	<i>Helicobacter pylori</i> DNA isolation in the stool: an essential pre-requisite for bacterial noninvasive molecular analysis. Scandinavian Journal of Gastroenterology, 2016, 51, 1429-1432.	0.6	27
24	The Interaction Between Celiac Disease and Intestinal Microbiota. Journal of Clinical Gastroenterology, 2016, 50, S145-S147.	1.1	26
25	<i>Helicobacter pylori</i> and Nonmalignant Diseases. Helicobacter, 2014, 19, 27-31.	1.6	25
26	Evolution of nonspecific duodenal lymphocytosis over 2 years of follow-up. World Journal of Gastroenterology, 2015, 21, 7545.	1.4	25
27	Differences in dietary habits between patients with inflammatory bowel disease in clinical remission and a healthy population. Annals of Gastroenterology, 2018, 31, 469-473.	0.4	24
28	Acute pancreatitis in elderly patients: A retrospective evaluation at hospital admission. European Journal of Internal Medicine, 2016, 30, 88-93.	1.0	23
29	Chemoprevention of inflammation-related colorectal cancer by silymarin-, acetyl-11-keto-beta-boswellic acid-, curcumin- and maltodextrin-enriched dietetic formulation in animal model. Carcinogenesis, 2018, 39, 1274-1282.	1.3	23
30	Lymphocytic duodenitis or microscopic enteritis and gluten-related conditions: what needs to be explored?. Annals of Gastroenterology, 2017, 30, 380-392.	0.4	23
31	Intestinal microbial metabolism of phosphatidylcholine: a novel insight in the cardiovascular risk scenario. Hepatobiliary Surgery and Nutrition, 2015, 4, 289-92.	0.7	22
32	Sequential vs. prolonged 14-day triple therapy for <i>Helicobacter pylori</i> eradication: the meta-analysis may be influenced by "geographical weighting". International Journal of Clinical Practice, 2015, 69, 1112-1120.	0.8	21
33	Systematic review: Renin-angiotensin system inhibitors in chemoprevention of hepatocellular carcinoma. World Journal of Gastroenterology, 2019, 25, 2524-2538.	1.4	21
34	Stool Investigations for Colorectal Cancer Screening: From Occult Blood Test to DNA Analysis. Journal of Gastrointestinal Cancer, 2016, 47, 143-151.	0.6	20
35	T Helper Lymphocyte and Mast Cell Immunohistochemical Pattern in Nonceliac Gluten Sensitivity. Gastroenterology Research and Practice, 2017, 2017, 1-9.	0.7	19
36	<i>Helicobacter pylori</i> Primary and Secondary Genotypic Resistance to Clarithromycin and Levofloxacin Detection in Stools: A 4-Year Scenario in Southern Italy. Antibiotics, 2020, 9, 723.	1.5	17

#	ARTICLE	IF	CITATIONS
37	Does Infliximab Short Infusion have a Beneficial Impact on the Quality of Life in Patients with Inflammatory Bowel Diseases? A Single Centre Prospective Evaluation. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 24, 165-170.	0.5	17
38	May the assessment of baseline mucosal molecular pattern predict the development of gluten related disorders among microscopic enteritis?. <i>World Journal of Gastroenterology</i> , 2016, 22, 8017.	1.4	17
39	Prevalence and associated factors of obesity in inflammatory bowel disease: A case-control study. <i>World Journal of Gastroenterology</i> , 2020, 26, 7528-7537.	1.4	16
40	Serrated Colorectal Lesions: An Up-to-Date Review from Histological Pattern to Molecular Pathogenesis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4461.	1.8	15
41	Endothelial function and cardiovascular risk in patients with inflammatory bowel disease in remission phase. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 253-255.	0.6	13
42	The Spectrum of Small Intestinal Lesions in Patients with Unexplained Iron Deficiency Anemia Detected by Video Capsule Endoscopy. <i>Medicina (Lithuania)</i> , 2019, 55, 59.	0.8	13
43	Non Steroidal Anti-Inflammatory Drug Induced Damage on Lower Gastro-Intestinal Tract: Is There an Involvement of Microbiota?. <i>Current Drug Safety</i> , 2014, 9, 196-204.	0.3	13
44	Experience with Rifabutin-Containing Therapy in 500 Patients from the European Registry on <i>Helicobacter pylori</i> Management (Hp-EuReg). <i>Journal of Clinical Medicine</i> , 2022, 11, 1658.	1.0	13
45	The sharp decline of beta estrogen receptors expression in long-lasting ulcerative-associated carcinoma. <i>Scandinavian Journal of Gastroenterology</i> , 2015, 50, 1002-1010.	0.6	12
46	Histamine and Histaminergic Receptors in Colorectal Cancer: From Basic Science to Evidence-based Medicine. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2018, 18, 15-20.	0.9	12
47	Reversal of IgM deficiency following a gluten-free diet in seronegative celiac disease. <i>World Journal of Gastroenterology</i> , 2014, 20, 17686.	1.4	12
48	Gastrointestinal bleeding from vascular malformations: Is octreotide effective to rescue difficult-to-treat patients?. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2016, 40, 373-377.	0.7	10
49	Predictivity of Autoimmune Stigmata for Gluten Sensitivity in Subjects with Microscopic Enteritis: A Retrospective Study. <i>Nutrients</i> , 2018, 10, 2001.	1.7	10
50	Detection of <i>Helicobacter pylori</i> DNA sequences in gastric biopsy samples to refine the diagnosis and therapy. <i>Journal of Medical Microbiology</i> , 2015, 64, 788-789.	0.7	10
51	Pathological and Clinical Correlation between Celiac Disease and <i>Helicobacter Pylori</i> Infection; a Review of Controversial Reports. <i>Middle East Journal of Digestive Diseases</i> , 2016, 8, 85-92.	0.2	10
52	Silymarin, boswellic acid and curcumin enriched dietetic formulation reduces the growth of inherited intestinal polyps in an animal model. <i>World Journal of Gastroenterology</i> , 2020, 26, 1601-1612.	1.4	10
53	Novel frontiers of agents for bowel cleansing for colonoscopy. <i>World Journal of Gastroenterology</i> , 2021, 27, 7748-7770.	1.4	10
54	Chronic Viral Hepatitis in a Cohort of Inflammatory Bowel Disease Patients from Southern Italy: A Case-Control Study. <i>Pathogens</i> , 2020, 9, 870.	1.2	9

#	ARTICLE	IF	CITATIONS
55	Mucosal molecular pattern of tissue transglutaminase and interferon gamma in suspected seronegative celiac disease at marsh 1 and 0 stages. Saudi Journal of Gastroenterology, 2015, 21, 379.	0.5	9
56	Estrogen Receptors in Colorectal Cancer: Facts, Novelties and Perspectives. Current Oncology, 2021, 28, 4256-4263.	0.9	9
57	Biological markers for non-celiac gluten sensitivity: a question awaiting for a convincing answer. Gastroenterology and Hepatology From Bed To Bench, 2018, 11, 203-208.	0.6	9
58	<i>Helicobacter pylori</i> , liver cirrhosis, and portal hypertension: an updated appraisal. Immunopharmacology and Immunotoxicology, 2016, 38, 408-413.	1.1	8
59	Safety and efficacy of switching from infliximab biosimilar CT-P13 to infliximab biosimilar SB2 in patients with inflammatory bowel disease. European Journal of Gastroenterology and Hepatology, 2021, 32, 201-207.	0.8	8
60	Tailored therapy guided by multichannel intraluminal impedance pH monitoring for refractory non-erosive reflux disease. Cell Death and Disease, 2017, 8, e3040-e3040.	2.7	7
61	A Case of Severe Transaminase Elevation Following a Single Ustekinumab Dose with Remission After Drug Withdrawal. Current Drug Safety, 2018, 13, 221-223.	0.3	7
62	Epithelial turnover in duodenal familial adenomatous polyposis: A possible role for estrogen receptors?. World Journal of Gastroenterology, 2016, 22, 3202.	1.4	7
63	Low Molecular Weight Heparin in Portal Vein Thrombosis of Cirrhotic Patients: Only Therapeutic Purposes?. Scientific World Journal, The, 2014, 2014, 1-6.	0.8	6
64	Rifabutin-based 10-day and 14-day triple therapy as a third-line and fourth-line regimen for <i>Helicobacter pylori</i> eradication: how should rifabutin be managed in rescue regimens?. United European Gastroenterology Journal, 2016, 4, 474-475.	1.6	6
65	What Is the Optimal Follow-up Time to Ascertain the Safety of Proton Pump Inhibitors?. Gastroenterology, 2020, 158, 1175.	0.6	6
66	Liver involvement in inflammatory bowel disease: What should the clinician know?. World Journal of Hepatology, 2021, 13, 1534-1551.	0.8	6
67	Letter: <i>Helicobacter</i> -negative gastritis - a distinct condition?. Alimentary Pharmacology and Therapeutics, 2015, 41, 597-598.	1.9	5
68	Letter: could sequential therapy extended to 14 days replace prolonged triple regimens for <i>Helicobacter pylori</i> treatment?. Alimentary Pharmacology and Therapeutics, 2016, 43, 844-845.	1.9	5
69	Might <i>Helicobacter pylori</i> play a role in allergic or cross-reaction related disorders?. Expert Review of Gastroenterology and Hepatology, 2020, 14, 643-646.	1.4	5
70	<i>Helicobacter pylori</i> Antibiotic Resistance: Stewardship, Tailored Therapies, and Future Perspectives. Gastroenterology, 2021, 161, 1071-1072.	0.6	5
71	Intraepithelial lymphocytes: bystanders or causative factors in functional gastrointestinal disorders?. Cellular and Molecular Immunology, 2021, 18, 1620-1621.	4.8	5
72	Serologic diagnosis of celiac disease: May it be suitable for adults?. World Journal of Gastroenterology, 2021, 27, 7233-7239.	1.4	5

#	ARTICLE	IF	CITATIONS
73	Novel steps forward in the histopathology of non-celiac gluten sensitivity. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 473, 523-523.	1.4	4
74	Empiric "Three-in-One" Bismuth Quadruple Therapy for Second-Line <i>Helicobacter pylori</i> Eradication: An Intervention Study in Southern Italy. <i>Antibiotics</i> , 2022, 11, 78.	1.5	4
75	Assessment of body composition: Intrinsic methodological limitations and statistical pitfalls. <i>Nutrition</i> , 2022, 102, 111736.	1.1	4
76	Inter-Observer Agreement of a New Endoscopic Score for Ulcerative Colitis Activity: Preliminary Experience. <i>Diagnostics</i> , 2020, 10, 213.	1.3	3
77	Endoscopic stenting for colorectal cancer obstruction as a bridge-to-surgery strategy. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13252.	1.7	3
78	A prospective trial in Saudi Arabia comparing the 14-day standard triple therapy with the 10-day sequential therapy for treatment of <i>Helicobacter Pylori</i> infection: A further confirmation of "Geographic Weight". <i>Saudi Journal of Gastroenterology</i> , 2016, 22, 77.	0.5	3
79	Letter: tumour necrosis factor alpha blocker switching - a not so simple pharmacokinetic. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 1302-1302.	1.9	2
80	Editorial: liver transplantation in patients with non-alcoholic fatty liver disease and obesity" authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 460-461.	1.9	2
81	Trends of Liver Stiffness in Inflammatory Bowel Disease with Chronic Hepatitis C. <i>Diagnostics</i> , 2020, 10, 1037.	1.3	2
82	Future challenges in gastroenterology and hepatology, between innovations and unmet needs: A SIGE Young Editorial Board's perspective. <i>Digestive and Liver Disease</i> , 2021, , .	0.4	2
83	Role of concomitant therapy for <i>Helicobacter pylori</i> eradication: A technical note. <i>World Journal of Gastroenterology</i> , 2016, 22, 8638.	1.4	2
84	May Antitransglutaminase Levels Predict Severity of Duodenal Lesions in Adults with Celiac Disease?. <i>Medicina (Lithuania)</i> , 2021, 57, 1212.	0.8	2
85	Letter: portal vein obstruction " which subset of patients could benefit the most?. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 909-909.	1.9	1
86	P.16.15 FAMILIAL ADENOMATOUS POLYPOSIS SMALL BOWEL SURVEILLANCE: COULD INDICATORS FOR VIDEO-CAPSULE ENDOSCOPY BE ASCERTAINED?. <i>Digestive and Liver Disease</i> , 2016, 48, e211.	0.4	1
87	OC.10.3 SILYMARIN, BOSWELLIC ACID, CURCUMIN AND MALTODEXTRIN ENRICHED DIETETIC FORMULATION REDUCES THE GROWTH OF INHERITED INTESTINAL POLYPS IN AN ANIMAL MODEL. <i>Digestive and Liver Disease</i> , 2019, 51, e104.	0.4	1
88	Familial adenomatous polyposis small bowel surveillance: could indicators for video-capsule endoscopy be ascertained?. <i>Minerva Gastroenterologica E Dietologica</i> , 2016, 62, 272-3.	2.2	1
89	Letter: dose-response analysis revealed closer relationship between obesity and perioperative outcomes in patients after liver transplantation" Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 312-313.	1.9	0
90	P797 Costs distribution of conventional or biologic drugs in ulcerative colitis and Crohn's disease: A single outpatient centre experience. <i>Journal of Crohn's and Colitis</i> , 2018, 12, S514-S515.	0.6	0

#	ARTICLE	IF	CITATIONS
91	An uncommon etiology of pancreatitis after endoscopic ultrasound-guided fine needle aspiration. <i>Endoscopy</i> , 2020, 52, E106-E107.	1.0	0
92	Human Leukocyte Antigen (HLA) Haplotype Does Not Influence the Inflammatory Pattern of Duodenal Lymphocytosis Linked to Irritable Bowel Syndrome. <i>Medicina (Lithuania)</i> , 2020, 56, 660.	0.8	0
93	Sequential Therapy For <i>Helicobacter pylori</i> in Elderly Patients: Effectiveness, Safety and Predictors of Success. <i>Letters in Drug Design and Discovery</i> , 2017, 14, 500-505.	0.4	0